GO
Loading...

Enter multiple symbols separated by commas

CVS Health Corp

More

  • Early movers: KO, CVS, HOT, HD, GPS & more Tuesday, 10 Feb 2015 | 7:51 AM ET
    Traders work on the floor of the New York Stock Exchange, Feb. 9, 2015.

    Some of the names on the move ahead of the open.

  • Will early data back up the blowout jobs report? Tuesday, 10 Feb 2015 | 6:41 AM ET
    A now-hiring sign is shown in the window of a Panera Bread store in Santa Monica, Calif.

    Investors are looking at further confirmation of an improving U.S. job market with two data points that come out on Tuesday.

  • Here's how a janitor amassed an $8M fortune Monday, 9 Feb 2015 | 6:44 PM ET
    In this December 2011 photo, Connie Howe pours coffee for Ronald Read, left, and Dave Smith during the Charlie Slate Memorial Christmas breakfast at the American Legion in Brattleboro, Vt.

    A Vermont gas station attendant and janitor, invested in recognizable names when he amassed an $8 million fortune, his attorney said.

  • Cramer game plan: Next week's hot stocks to watch Friday, 6 Feb 2015 | 6:09 PM ET
    Game plan strategy

    Jim Cramer sees that the market is in a sweet spot for earnings. With a new landscape, he's betting that these are the hot stocks to watch.

  • Pricing wars heat up over hepatitis C drugs Wednesday, 4 Feb 2015 | 12:13 PM ET
    A researcher works on a hepatitis C virus drug at Gilead Sciences lab in Foster City, Calif.

    Discounts on Gilead's hepatitis C drugs this year will be 46 percent, way more than investors and analysts expected.

  • Doctors' group joins fight against high drug prices Tuesday, 3 Feb 2015 | 3:34 PM ET
    An undated handout photo provided by Gilead Sciences shows the hepatitis-C medication Sovaldi.

    A leading group of physicians is warning that high prices of specialty drugs is creating barriers to care for patients.

  • Jan 30- AbbVie Inc's chief executive said on Friday the company's new oral hepatitis C treatment Viekira Pak has the potential to capture a "meaningful share" of the U.S. market, where it is competing against Gilead Sciences. AbbVie CEO Richard Gonzalez told investors the company expects an annualized sales run rate of more than $3 billion by the end of 2015, which...

  • Drugmaker AbbVie beats as Humira sales rise Friday, 30 Jan 2015 | 11:34 AM ET
    AbbVie facility in Ireland

    U.S. drugmaker AbbVie's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent.

  • Jan 30- U.S. drugmaker AbbVie Inc's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent. Excluding the charge and other special items, AbbVie earned 89 cents per share. Sales of Humira, which AbbVie inherited from Abbott Laboratories in 2013, rose to $3.36 billion in the fourth quarter ended...

  • Cramer Remix: I've never seen anything like this Tuesday, 27 Jan 2015 | 7:13 PM ET
    Jim Cramer on Mad Money.

    In more than 30 years around Wall Street, “Mad Money” host Jim Cramer has seen a lot, but not this.

  • Cramer: Super Bowl stock face-off—Seahawks or NE? Tuesday, 27 Jan 2015 | 6:43 PM ET
    Super Bowl Phoenix Convention Center

    Seattle or New England? Jim Cramer goes off the charts with 4 companies.

  • Jan 26- Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc's hepatitis C drugs on an exclusive basis, the latest Gilead victory in a market share battle with AbbVie over their new treatments for the liver destroying virus. EnvisionRx said Gilead's Sovaldi and its newer two-drug...

  • Early movers: UNH, AAPL, NSP, NFLX, AMD & more Wednesday, 21 Jan 2015 | 8:05 AM ET

    Some of the names on the move ahead of the open.

  • Investors are watching closely to see how insurers decide to cover these drugs, which cost tens of thousands of dollars per treatment, after AbbVie Inc started a competitor to Gilead Sciences' breakthrough hepatitis C treatment. Express Scripts, the largest pharmacy benefit manager in the United States, dropped Gilead Sciences hepatitis C drugs from its main...

  • Your first trade for Wednesday Tuesday, 13 Jan 2015 | 6:14 PM ET
    Fast Money Final Trade: FXC, EWZ, M, TLT

    The "Fast Money" traders give their final trades of the day.

  • Jan 8- Health insurer Anthem Inc on Thursday said it reached a deal under which Gilead Sciences Inc's hepatitis C drug Harvoni will be the primary treatment for patients infected with the most common strain of the liver-destroying virus. Last month, AbbVie Inc began sales of a competing drug, Viekira Pak, at a similar list price. Express Scripts Holding Co, the...

  • Jan 8- AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. U.S. health regulators approved Viekira Pak, AbbVie's all-oral treatment for hepatitis C in December. AbbVie's newly approved regimen is also cheaper than Gilead's...

  • Cramer Remix: This stock can go a lot higher Wednesday, 7 Jan 2015 | 7:19 PM ET

    "Mad Money" host Jim Cramer actually suggests buying it into the next oil-induced selloff.

  • Flu boosts drug store sales, but others take a hit Wednesday, 7 Jan 2015 | 10:24 AM ET
    A woman receiving a flu vaccination in San Pablo, Calif.

    This year’s flu season is shaping up to be as bad as expected. That's good news for drug stores, but insurers and others could suffer.

  • Cramer Remix: Buy into this weakness Tuesday, 6 Jan 2015 | 7:03 PM ET
    Jim Cramer on Mad Money.

    The recent selloffs have been ugly, but "Mad Money" host Jim Cramer thinks you can buy these stocks into the red arrows.